Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

(2018) Hagop Kantarjian et al.   LANCET ONCOLOGY

Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia

(2018) Elias Jabbour et al.   JAMA Oncology

Liver complications following treatment of hematologic malignancy with anti-cd22-calicheamicin (Inotuzumab Ozogamicin)

(2018) George B McDonald et al.   HEPATOLOGY

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia

(2018) Ilana R Yurkiewicz et al.   Drug Design Development and Therapy

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

(2017) Hagop M Kantarjian et al.   Lancet Haematology

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

(2016) Ludovic Trinquart et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

(2015) Hajime Uno et al.   ANNALS OF INTERNAL MEDICINE

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

(2015) Boris Shor et al.   MOLECULAR IMMUNOLOGY

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

(2012) N. Gokbuget et al.   BLOOD

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review

(2011) Denise M. Oliansky et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

(2011) Patrick Royston et al.   STATISTICS IN MEDICINE

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

(2008) Susan O'Brien et al.   CANCER